1. Pain terms: a list with definitions and notes on
usage. Recommended by IASP subcommittee on taxonomy. Pain
1979;
6: 249.
2. McCaffrey M, Ferrell BR.
Nurses’ knowledge of pain assessment and management: how much progress have we made?
J Pain Symptom Manage 1997; 14: 175-188.
3. Breivik H, Borchgrevink
PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J
Anaesth 2008;
101: 17-24.
4. Andrew D, Greenspan JD.
Mechanical and heat sensitization of cutaneous nociceptors after peripheral inflammation
in the rat. J Neurophysiol 1999; 82: 2649-2656.
5. Monafo WW. Physiology
of Pain. J Burn Care Rehabil 1995; 16: 345-347.
6. Turk DC, Dworkin RH. What
should be the core outcomes in chronic pain clinical trials? Arthritis
Res Ther 2004;
6: 151-154.
7. Salter MW. Cellular neuroplasticity
mechanisms mediating pain persistence. J Orofac Pain 2004; 18: 318-324
8. Rosen SD, Camici PG. The
brain-heart axis in the perception of cardiac pain: the elusive link between ischaemia
and pain. Ann Med
2000; 32: 350-364.
9. Jacques A. Physiology
of pain. Br J Nurs
1994; 3: 607-610. Review.
10. Burke RE. Sir Charles Sherrington’s the integrative
action of the nervous system: a centenary appreciation. Brain 2007; 130: 887-894.
11. Loeser JD, Treede RD. The Kyoto protocol of IASP
Basic Pain Terminology. Pain 2008; 137: 473-477.
12. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky
JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical
and research purposes. Neurology 2008; 70: 1630-1635.
13. Dworkin RH, O’Connor AB, Backonja M, Farrar JT,
Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based
recommendations. Pain 2007; 132: 237-251.
14. Harper AC, Harper DA, Lambert LJ, Andrews HB, Lo
SK, Ross FM, et al. Symptoms of impairment, disability and handicap in low back
pain: a taxonomy. Pain 1992; 50: 189-195.
15. Okifuji A. Interdisciplinary pain management with
pain patients: evidence for its effectiveness. Seminars in Pain Medicine 2003; 1: 110-119.
16. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd
B, Koltzenburg M, et al. Towards a mechanism-based classification of pain? Pain 1998; 77: 227-229.
17. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353: 2051-2058. Review
18. Gunnarsdottir S, Serlin RC, Ward S. Patient-related
barriers to pain management: the Icelandic Barriers Questionnaire II. J Pain
Symptom Manage
2005; 29: 273-285.
19. Koyama T, McHaffie JG, Laurienti PJ, Coghill RC.
The subjective experience of pain: where expectations become reality. Proc
Natl Acad Sci U S A
2005; 102: 12950-12955.
20. Bertakis KD, Azari R, Callahan EJ. Patient pain
in primary care: factors that influence physician diagnosis. Ann Fam
Med 2004;
2: 224-230.
21. Fink R. Pain assessment: the cornerstone to optimal
pain management. Proc (Bayl Univ Med Cent) 2000; 13: 236-239.
22. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne
KS, Peirce-Sandner S, et al. Development and initial validation of an expanded and
revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2). Pain 2009; 144: 35-42.
23. Hicks CL, von Baeyer CL, Spafford PA, van Korlaar
I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric
pain measurement. Pain 2001; 93: 173-183.
24. Barkin RL, Barkin D. Pharmacologic management of
acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic
selection. South Med J 2001; 94: 756-770.
25. Hallenbeck J. Palliative care perspectives. Oxford:
Oxford University Press; 2003.
26. Lockermann G. Friedrich Wilhelm Serturner, the discoverer
of morphine. Journal of Chemical Education 1951; 28: 277.
27. Herman RJ, McAllister CB, Branch RA, Wilkinson GR.
Effects of age on meperidine disposition. Clin Pharmacol Ther 1985; 37: 19-24.
28. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI,
Galligan JJ, et al. Bis-penicillamine enkephalins possess highly improved specificity
toward delta opioid receptors. Proc Natl Acad Sci U S A 1983; 80: 5871-5874.
29. Wang RA, Randic M. Activation of mu-opioid receptor
modulates GABAA receptor-mediated currents in isolated spinal dorsal horn neurons.
Neurosci Lett 1994; 180: 109-113.
30. Duggan AW, North RA. Electrophysiology of opioids.
Pharmacol Rev 1983; 35: 219-281.
31. Akil H, Meng F, Devine DP, Watson SJ. Molecular
and Neuroanatomical Properties of the Endogenous Opioid System: Implications for
Treatment of Opiate Addiction. Seminars in Neuroscience 1997; 9: 70-83.
32. Martin WR. Pharmacology of opioids. Pharmacol
Rev 1983;
35: 283-323.
33. Anand KJ, Willson DF, Berger J, Harrison R, Meert
KL, Zimmerman J, et al. Tolerance and withdrawal from prolonged opioid use in critically
ill children. Pediatrics 2010; 125: e1208-e1225.
34. Trujillo KA, Akil H. Inhibition of morphine tolerance
and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251: 85-87.
35. Bloom FE. Endogenous opioids. Histochemistry, neurophysiology,
and pharmacology. Psychiatr Clin North Am 1983; 6: 365-375.
36. Authier N, Balayssac D, Sautereau M, Zangarelli
A, Courty P, Somogyi AA, et al. Benzodiazepine dependence: focus on withdrawal syndrome.
Ann Pharm Fr 2009; 67: 408-413.
37. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF,
Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of
sparteine: pharmacokinetics, analgesic effect and side effects. Eur J
Clin Pharmacol
1996; 51: 289-295.
38. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic
effect of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45-52.
39. Razaq M, Balicas M, Mankan N. Use of hydromorphone
(Dilaudid) and morphine for patients with hepatic and renal impairment. Am J
Ther 2007;
14: 414-416.
40. Benedetti C, Butler SH. Systemic analgesics. In:
Bonica JJ, editor. The management of pain. 2nd ed. Philadelphia (PA): Lea &
Febiger; 1990. p. 1640–1675.
41. Turgeon J, Gröning R, Sathyan G, Thipphawong J,
Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation.
Expert Opin Drug Deliv 2010; 7: 137-144.
42. Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen
K, Hansen SH, et al. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone
concentrations and analgesic effect in a multimodal experimental pain model. J Clin
Pharmacol 2008;
48: 619-631.
43. Rudin Ö, Lundberg JF, Hammarlund-Udenaes M, Flisberg
P, Werner MU. Morphine metabolism after major liver surgery. Anesth
Analg 2007;
104: 1409-1414.
44. Saari TI, Grönlund J, Hagelberg NM, Neuvonen M,
Laine K, Neuvonen P, et al. Effects of itraconazole on the pharmacokinetics and
pharmacodynamics of intravenously and orally administered oxycodone. Eur J
Clin Pharmacol
2010; 66: 387-397.
45. Bodd E, Jacobsen D, Lund E, Ripel A, Morland J,
Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect
of morphine in acute renal failure. Hum Exp Toxicol 1990; 9: 317-321.
46. Peng PW, Sandler AN. A review of the use of fentanyl
analgesia in the management of acute pain in adults. Anesthesiology
1999;
90: 576-599. Review.
47. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives,
diversion and routes of administration associated with nonmedical use of prescription
opioids. Addict Behav 2007; 32: 562-575.
48. Bruera E, Sweeney C. Methadone use in cancer patients
with pain: a review. J Palliat Med 2002; 5: 127-138.
49. Eap CB, Buclin T, Baumann P. Interindividual variability
of the clinical pharmacokinetics of methadone: implications for the treatment of
opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193.
50. Kharasch ED, Hoffer C, Whittington D, Walker A,
Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A)
activity and gastrointestinal drug transport: insights from methadone interactions
with ritonavir/indinavir. Anesthesiology 2009; 110: 660-672.
51. Moolchan ET, Umbricht A, Epstein D. Therapeutic
drug monitoring in methadone maintenance: choosing a matrix. J Addict
Dis 2001;
20: 55-73.
52. Derry S, Moore RA, McQuay HJ. Single dose oral codeine,
as a single agent, for acute postoperative pain in adults. Cochrane
Database Syst Rev
2010 (4): CD008099.
53. Thorn CF, Klein TE, Altman RB. Codeine and morphine
pathway. Pharmacogenet Genomics 2009; 19: 556-568.
54. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer
TR, Abdi S, et al. Opioid guidelines in the management of chronic non-cancer pain.
Pain Physician 2006; 9: 1-39. Review.
55. Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic
drug interactions of synthetic opiate analgesics. Psychosomatics
2009;
50: 169-176. Review.
56. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody
DE, Kilbourn M, et al. Buprenorphine duration of action: mu-opioid receptor availability
and pharmacokinetic and behavioral indices. Biol Psychiatry 2007; 61: 101-110.
57. Park I, Kim D, Song J, In C, Jeong SW, Lee S, et
al. Buprederm, a new Transdermal Delivery System of Buprenorphine: Pharmacokinetic,
Efficacy and Skin Irritancy Studies. Pharmaceutical Research 2008; 25: 1052-1062.
58. Buchanan WW, Kean WF. The treatment of acute rheumatism
by salicin, by T.J. Maclagan--The Lancet, 1876. J Rheumatol 2002; 29: 1321-1323.
59. Sneader W. The discovery of aspirin: a reappraisal.
BMJ
2000; 321: 1591-1594.
60.
Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl 5: 13-23.
61. Trinca F. Mechanism of Inflammation. British
Medical Journal 1941;
2: 285.
62. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse
effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on
upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010; 24: 121-132.
63. Winkelmayer WC, Waikar SS, Mogun H, Solomon DH.
Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J
Med 2008;
121: 1092-1098.
64. Bessone F. Non-steroidal anti-inflammatory drugs:
What is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-5661. Review.
65. Hitomi Y, Ebisawa M, Tomikawa M, Imai T, Komata
T, Hirota T, et al. Associations of functional NLRP3 polymorphisms with susceptibility
to food-induced anaphylaxis and aspirin-induced asthma. J Allergy
Clin Immunol
2009; 124: 779-785.
66. Bagchi S. Aspirin: The Remarkable Story of a Wonder
Drug. JAMA
2005; 293: 1268-1269.
67. Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad
MO, Zakharov AD, Lubet R, et al. Comparison of pharmacokinetic and pharmacodynamic
profiles of aspirin following oral gavage and diet dosing in rats. Chem
Biol Interact
2009; 179: 233-239.
68. Sparatore A, Perrino E, Tazzari V, Giustarini D,
Rossi R, Rossoni G, et al. Pharmacological profile of a novel H2S-releasing aspirin.
Free Radic Biol Med 2009; 46: 586-592.
69.
Malhotra S, Shafiq N, Pandhi P. COX-2 inhibitors: a CLASS act or Just VIGORously
promoted. MedGenMed
2004; 6: 6.
70. Chen LC, Ashcroft DM. Do selective COX-2 inhibitors
increase the risk of cerebrovascular events? A meta-analysis of randomized controlled
trials. J Clin Pharm Ther 2006; 31: 565-576.
71. Mestre AS, Pires J, Nogueira JM, Parra JB, Carvalho
AP, Ania CO. Waste-derived activated carbons for removal of ibuprofen from solution:
role of surface chemistry and pore structure. Bioresour Technol 2009; 100: 1720-1726.
72. Hedner T, Everts B. The early clinical history of
salicylates in rheumatology and pain. Clin Rheumatol 1998; 17: 17-25.
73. Singh N, Kumar RP, Kumar S, Sharma S, Mir R, Kaur
P, et al. Simultaneous inhibition of anti-coagulation and inflammation: crystal
structure of phospholipase A2 complexed with indomethacin at 1.4 A resolution reveals
the presence of the new common ligand-binding site. J Mol
Recognit 2009;
22: 437-445.
74. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison
of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy
in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled
trial. Ann Emerg Med 2007; 49: 670-677.
75. Bradley N. Naming of drugs. BMJ should use “paracetamol”
instead of “acetaminophen” in its index. BMJ 1996; 313: 689.
76. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi
R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug
Rev 2006;
12: 250-275.
77. Dubach UC, Rosner B, Sturmer T. An epidemiologic
study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality
and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324: 155-160.
78. Brodie BB, Axelrod J. The fate of acetanilide in
man. J Pharmacol Exp Ther 1948; 94: 29-38.
79.
Travis AS. Manufacture and Uses of the Anilines: A Vast Array of Processes and Products.
KGaA, Weinheim (DE): John Wiley & Sons, Ltd; 2009.
80. Kam PCA, So A. COX-3: Uncertainties and controversies.
Current Anaesthesia & Critical Care 2009; 20: 50-53.
81. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E,
Carbonell Abello J, Linares Ferrando LF, Tornero Molina J, et al. Aceclofenac vs
paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind
6-week randomized controlled trial. Osteoarthritis Cartilage 2007; 15: 900-908.
82. Jahr JS, Lee VK. Intravenous acetaminophen. Anesthesiol
Clin 2010;
28: 619-645.
83. Bin Nor Aripin KN, Choonara I. The management of
paracetamol poisoning. Paediatrics and Child Health 2009; 19: 492-497.
84. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory
drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis,
and prevention. Gastroenterol Clin North Am 2010; 39: 433-464.
85. Prescott LF, Wright N. The effects of hepatic and
renal damage on paracetamol metabolism and excretion following overdosage. A pharmacokinetic
study. Br J Pharmacol 1973; 49: 602-613.
86. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary
review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
in acute and chronic pain states. Drugs 1993; 46: 313-340. Review.
87. Nossaman VE, Ramadhyani U, Kadowitz PJ, Nossaman
BD. Advances in perioperative pain management: use of medications with dual analgesic
mechanisms, tramadol & tapentadol. Anesthesiol Clin 2010; 28: 647-666.
88. Goldenberg DL. Pharmacological treatment of fibromyalgia
and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol 2007; 21: 499-511.
89. dos Santos TO, Estrela TG, de Azevedo VL, de Oliveira
OE, Oliveira G Jr, Figueiredo Gda S. Intravenous and subcutaneous tramadol for inguinal
herniorrhaphy: comparative study. Rev Bras Anestesiol 2010; 60: 522-527.
90. Garcia-Quetglas E, Azanza JR, Sadaba B, Munoz MJ,
Gil I, Campanero MA. Pharmacokinetics of tramadol enantiomers and their respective
phase I metabolites in relation to CYP2D6 phenotype. Pharmacol
Res 2007;
55: 122-130.
91. Moore KA, Cina SJ, Jones R, Selby DM, Levine B,
Smith ML. Tissue distribution of tramadol and metabolites in an overdose fatality.
Am J Forensic Med Pathol 1999; 20: 98-100.
92. Livingstone KD, Lackney
VK, Blauth JR, van Wijk R, Jahn MK. Genome mapping in capsicum and the evolution
of genome structure in the solanaceae. Genetics 1999; 152: 1183-1202.
93. Lee Y, Howard LR, Villalon
B. Flavonoids and Antioxidant Activity of Fresh Pepper (Capsicum annuum) Cultivars.
J Food Sci
1995; 60: 473-476.
94. Aburjai T, Hudaib M,
Tayyem R, Yousef M, Qishawi M. Ethnopharmacological survey of medicinal herbs in
Jordan, the Ajloun Heights region. J Ethnopharmacol 2007; 110: 294-304.
95. Coe FG. Rama midwifery
in eastern Nicaragua. J Ethnopharmacol 2008; 117: 136-157.
96. Yamamoto S, Nawata E.
Use of Capsicum frutescens L. by the Indigenous Peoples of Taiwan and the Batanes
Islands. Economic Botany 2009; 63: 43-59.
97. Teklehaymanot T. Ethnobotanical
study of knowledge and medicinal plants use by the people in Dek Island in Ethiopia.
J Ethnopharmacol 2009; 124: 69-78.
98. Jernigan KA. Barking
up the same tree: a comparison of ethnomedicine and canine ethnoveterinary medicine
among the Aguaruna. J Ethnobiol Ethnomed 2009; 5: 33.
99. Valadeau C, Castillo
JA, Sauvain M, Lores AF, Bourdy G. The rainbow hurts my skin: medicinal concepts
and plants uses among the Yanesha (Amuesha), an Amazonian Peruvian ethnic group.
J Ethnopharmacol 2010; 127: 175-192.
100. Caterina MJ, Julius D. The vanilloid receptor: a
molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517.
101. Westaway SM. The potential of transient receptor
potential vanilloid type 1 channel modulators for the treatment of pain. J Med
Chem 2007;
50: 2589-2596.
102. Butera JA. Current and emerging targets to treat
neuropathic pain. J Med Chem 2007; 50: 2543-2546.
103. Hayman M, Kam PCA. Capsaicin: A review of its pharmacology
and clinical applications. Current Anaesthesia & Critical
Care 2008;
19: 338-343.
104. See S, Ginzburg R. Choosing a skeletal muscle relaxant.
Am Fam Physician 2008; 78: 365-370.
105. Chou R, Huffman LH, American Pain Society; American
College of Physicians. Medications for acute and chronic low back pain: a review
of the evidence for an American Pain Society/American College of Physicians clinical
practice guideline. Ann Intern Med 2007; 147: 505-514.
106. McGeeney BE. Pharmacological management of neuropathic
pain in older adults: an update on peripherally and centrally acting agents. J Pain
Symptom Manage
2009; 38 (Suppl 2): S15-S27.
107. Buccafusco JJ, Terry AV Jr, Vazdarjanova A, Snutch
TP, Arneric SP. Treatments for neuropathic pain differentially affect delayed matching
accuracy by macaques: effects of amitriptyline and gabapentin. Pain 2010; 148: 446-453.
108. Ripamonti C, Bandieri E. Pain therapy. Crit
Rev Oncol Hematol 2009;
70: 145-159.
109. Reeve HS. Phenytoin in the treatment of trigeminal
neuralgia. Lancet
1961; 277: 404.
110. Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman
RB. 3-alkyl GABA and 3-alkylglutamic acid analogues: two new classes of anticonvulsant
agents. Epilepsy Res 1992; 11: 103-110.
111. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson
T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth
Eilat Conference (EILAT IX). Epilepsy Res 2009; 83: 1-43.
112. Rozen TD. Trigeminal neuralgia and glossopharyngeal
neuralgia. Neurol Clin 2004; 22: 185-206.
113. Annetta MG, Iemma D, Garisto C, Tafani C, Proietti
R. Ketamine: new indications for an old drug. Curr Drug Targets 2005; 6: 789-794. Review.
114. Fraceto LF, Oyama S Jr, Nakaie CR, Spisni A, de
Paula E, Pertinhez TA. Interaction of local anesthetics with a peptide encompassing
the IV/S4-S5 linker of the Na+ channel. Biophys Chem 2006; 123: 29-39.
115. White PF. The changing role of non-opioid analgesic
techniques in the management of postoperative pain. Anesth
Analg 2005;
101 (5 Suppl): S5-S22.
116. Carroll
IR, Kaplan KM, Mackey SC. Mexiletine therapy for chronic pain: survival analysis
identifies factors predicting clinical success. J Pain Symptom Manage 2008; 35: 321-326.